Cilostazol

CHEMBL799 Phase 4 승인됨 Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

369.5 g/mol

LogP

3.1

Phase

4

A phosphodiesterase 3 inhibitor that inhibits platelet aggregation and acts as a vasodilator, used to reduce symptoms of intermittent claudication in peripheral artery disease, improving walking distance. It is contraindicated in patients with heart failure of any severity because PDE3 inhibitors have been associated with increased mortality in this population. Headache and palpitations are common side effects reflecting its vasodilatory and cardiac effects.

분자량

369.5000 g/mol

LogP

3.10

TPSA

81.90 Å²

리핀스키 5의 법칙

통과

치료 영역

Cardiovascular Disease Pain Management Rheumatoid Arthritis Parkinson's Disease Migraine Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Stroke Hyperlipidemia Type 2 Diabetes Major Depressive Disorder Breast Cancer Chronic Pain Heart Failure Atrial Fibrillation

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D 구조

SVG PNG

Cite this structure

Embed this structure

SMILES

O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1

InChI

InChI=1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)

Molecular Formula

C20H27N5O2

HBD / HBA

1 / 5

회전 가능 결합

7

무거운 원자

27

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

A phosphodiesterase 3 inhibitor that inhibits platelet aggregation and acts as a vasodilator, used to reduce symptoms of intermittent claudication in peripheral artery disease, improving walking distance. It is contraindicated in patients with heart failure of any severity because PDE3 inhibitors have been associated with increased mortality in this population. Headache and palpitations are common side effects reflecting its vasodilatory and cardiac effects.

Yes, Cilostazol is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL799. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 2754. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

환자 친화적 정보를 찾고 계신가요?

Cilostazol PillFYI에서

구조

핵심 데이터

분자식: C20H27N5O2

외부 링크

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.